^
Association details:
| Biomarker: | CXCR4 expression |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | balixafortide (POL 6326) (CXCR4 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Balixafortide plus eribulin in HER2-negative metastatic breast cancer: a phase 1, single-arm, dose-escalation trial
Published date:
04/26/2018
Excerpt:
...preliminary phase 1 activity of the CXCR4 antagonist, balixafortide, in combination with eribulin chemotherapy in...histologically confirmed HER2-negative metastatic breast cancer, evidence of tumour cell CXCR4 expression...Objective responses (all partial responses) were observed in 16 (30%; 95% CI 18-44) of 54 patients who were evaluable for antitumour activity.
Secondary therapy:
eribulin mesylate
DOI:
10.1016/S1470-2045(18)30147-5
Trial ID:
